“Mamas, Don’t Let Your Babies Grow Up to be Cowboys” – country music song – Ed and Patsy Bruce
As the open range diminished in the United States, the above lyric was excellent advice. Today, songwriters could be penning a similar lyric: mamas, do not let your attorney sons and daughters grow up to be CEOs. The recent resignation of Pfizer CEO Jeffrey Kindler is a cautionary tale about elevating lawyers to CEO status.
A Great Legal Career
Mr. Kindler has a stellar and storied legal career: magna cum laude Harvard Law graduate, clerk for Supreme Court Justice William J. Brennan, attorney for the Federal Communications Commission, partner in the Williams & Connolly law firm, Vice President of Litigation and Legal Policy for GE, Executive Vice President and General Counsel of McDonalds Corporation. From 2000 to 2002 Mr. Kindler spent time in line management with McDonalds’ Partners Brand (Chipotle Grill, Boston Market and Pret a Manger). In January 2002 he returned to his legal career as Senior Vice President and General Counsel of Pfizer. Selected over two long term Pfizer employees, Mr. Kindler became Pfizer CEO in 2006. Source Wikepedia, SEC Filing
The following comments partially describe and analyze Mr. Kindler’s troubled tenure as Pfizer CEO:
…His tenure, though, has been far from smooth. Within months, Kindler was forced to announce that torcetrapib, which was supposed to have been a blockbuster cholesterol drug, had to be scrapped. Then, two highly touted product launches proved to be disappointments – the Exubera inhaled insulin … and the Chantrix anti-smoking pill.
Kindler eventually followed the same game plan as his predecessor – to appease Wall Street, he pursued a huge acquisition, which was the $68 billion purchase of Wyeth last year. This followed and extended a series of huge cuts across the company, including eliminating 14,000 jobs, several facilities and various R&D efforts….. Investors, however, have remained lukewarm, especially since Pfizer has endured several recent setbacks in the lab and as the patent expires next year on the best-selling Lipitor cholesterol pill. Pfizer stock, meanwhile, continues to languish.. See Jeff Kindler Unexpectedly Resigns as Pfizer CEO
To replace Mr. Kindler, Pfizer selected Ian Read, a company employee since 1978. Mr. Read had extensive domestic, international, and financial experience, all within Pfizer.
The Difficulty in Selecting a CEO
As a long term observer of CEO selection, the one clearest truism is the extreme difficulty in finding and selecting a good one. Two things suggest that Mr. Kindler was not the right selection in 2006. First, he had extremely limited knowledge of the pharmaceutical industry generally and Pfizer specifically. No matter how much intellectual horsepower he could muster, it was no substitute for being steeped in the science and culture of the industry and knowledge of the day to day operations of the company. Second, Mr. Kindler was an attorney by trade with only two years of line experience in his career. Let’s look more closely at that second problem.
Attorneys vs. CEOs
We attorneys have some solid career traits. We are educated to analyze a problem, dissect the issues, develop a legal strategy and then communicate that strategy clearly in both oral and written form to a client or ultimately a court. Law is a conservative process; that is, attorneys are charged to look at risk and any financial or criminal downside of an issue. Attorneys are called counselors for a reason. They are not deciders. They present options and courses of action to a client. Ultimately, the client must decide how to proceed: negotiate, litigate, or settle. Attorneys also are trained to be self sufficient. Working in a law firm, an attorney is more a group leader and project manager than a corporate executive. Trained litigators like Mr. Kindler assemble a team of junior attorneys, associates and paralegals for a case and when that case is resolved the team disbands. It is a constant process of personnel and skill recombination on behalf of one’s client, rather than any long term team building process.
By contrast, the best CEOs are ultimately team builders and strategic decision makers. They have both operational (line) and staff (finance, legal, human resources, etc.) responsibilities. They prefer to make decisions rather than just analyze and counsel. In a world requiring both thoughtful and rapid decision making as well as risk taking, an attorney/CEO is operating outside the usual legal comfort zone, experience and training. Moreover, a fine CEO must get highly knowledgeable and strong willed senior management to work together, a far cry from commanding a team of compliant junior partners and associates with the knowledge that the process will be short term.
Boards of Directors
An old corporate saw describing bad corporate governance goes something like this: if the company is having a financial problem, its Board will elevate the chief financial officer to be the CEO. Similarly, if the company has a manufacturing problem, an outstanding operations executive may be tapped for the highest executive position. In the case of Pfizer in particular, and the pharmaceutical industry in general, recent times have been beset with product liability law suits, patent infringement actions and threats of new legislation. The easy choice for Pfizer’s Board in 2006 was to select its general counsel or an outside law firm partner as CEO. That turned out to be a mistake. Clearly, what Pfizer did not do was keep its fine general counsel, Mr. Kindler, who would have continued to assemble and direct a first rate products liability and patent law legal team to tackle the problems. If Pfizer’s Board, at the same time, found a fine CEO to shepherd the company through its immediate problems and its long term issues, perhaps better company performance would have resulted.
Merck Follows Pfizer
In November 2010, in almost the same time frame as Mr. Kindler’s departure, the Merck Board appointed Kenneth Frazier as its CEO. Mr. Frazier is credited with devising the litigation strategy to deal with Merck’s Vioxx products liability suits. Mr. Frazier appears to have followed a parallel career path to Mr. Kindler. Working in various legal roles at Merck from 1992 to 2010, Mr. Frazier was not appointed to an operations role at the company until April 2010. In other words, he had a mere seven months of operational experience.
Merck has had a long and distinguished history of CEOs with scientific backgrounds. I would argue that the transition to CEOs with staff backgrounds, such as finance and law, has contributed to the company’s decline:
The key to understanding Merck’s slide is to compare its CEOs. During the glory days, it was led by scientist P. Roy Vagelos, who is almost universally described as brilliant, charismatic, arrogant, and hard-driving, both by industry experts and by people who worked with him….The son of Greek immigrants, Vagelos grew up cleaning tables in his family’s luncheonette, in the shadow of the Merck labs. As head of Merck’s R&D for nine years, he brought in hundreds of new scientists, modernized the labs, and increased the research budget an average of 17.2% annually. Because he understood the science, old-timers say, Vagelos was able to inspire …creativity and energy….Moreover, Vagelos got personally involved in the everyday workings of the company. He even ate lunch in the cafeteria. See Merck’s Fall from Grace
Perhaps Mr. Frazier will break the pattern of failed attorney CEOs. In hindsight, both Pfizer and Merck’s Boards would have been wiser to avoid selecting attorney CEOs and have their fine science companies led by a long-term company scientist with operations experience. For now, if I were investing in these companies (and I am not, nor am I purporting to provide investment advice), I would place my bet on Pfizer’s Mr. Read: a long term Pfizer employee with a scientific background and in-house financial and operations experience elevated to his company’s highest corporate position. Let’s see how he does.
loading...